{"data":{"id":"us-il/410-ilcs-649-5","jurisdiction":"us-il","citation":"410 ILCS 649/5","heading":"Findings.","body":"The General Assembly finds that the process of approval for investigational drugs, biological products, and devices in the United States often takes many years, and a patient with a terminal illness does not have the luxury of waiting until such drug, product, or device receives final approval from the United States Food and Drug Administration. As a result, the standards of the United States Food and Drug Administration for the use of investigational drugs, biological products, and devices may deny the benefits of potentially life-saving treatments to terminally ill patients. A patient with a terminal illness has a fundamental right to attempt to preserve his or her own life by accessing investigational drugs, biological products, and devices. Whether to use available investigational drugs, biological products, and devices is a decision that rightfully should be made by the patient with a terminal illness in consultation with his or her physician and is not a decision to be made by the government.","path":["CHAPTER 410 PUBLIC HEALTH","Right to Try Act."],"source_url":"https://www.ilga.gov/legislation/ILCS/details?ActID=3653\u0026ChapterID=35\u0026ChapAct=FullText\u0026Print=True","current_through":"at least Public Act 104-790","vintage":"","retrieved_at":"2026-09-15T04:46:36Z","sha256":"04534c445f890a7fe32db3a4b4df0f7328629bf7f9c7edeede8b3951ede2a54e","source_id":"us-il","stale":false,"prev":"us-il/410-ilcs-649-1","next":"us-il/410-ilcs-649-10"},"notice":"GroundRules: Original legal text. Not legal advice."}